false 0001865494 0001865494 2024-06-06 2024-06-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2024

 

 

IO Biotech, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41008   87-0909276

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   IOBT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 6, 2024, IO Biotech, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

Proposal One: Election of Class III Directors

Each of Kathleen Sereda Glaub, Peter Hirth, and Mai-Britt Zocca was elected to serve as a class III director to hold office until the Company’s 2027 Annual Meeting of Stockholders and until the election and qualification of his or her successor. Votes were cast as follows:

 

     For      Withheld      Broker Non-Votes  

Kathleen Sereda Glaub, M.B.A

      43,046,622        543,271        3,914,304  

Peter Hirth, Ph.D.

      42,380,396        1,209,497        3,914,304  

Mai-Britt Zocca, Ph.D.

      43,247,059        342,834        3,914,304  

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

47,215,146   66,992   222,059   —

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    IO Biotech, Inc.

Date: June 11, 2024

    

By:

  

/s/ Mai-Britt Zocca, Ph.D.

     

Mai-Britt Zocca, Ph.D.

     

Chief Executive Officer

v3.24.1.1.u2
Document and Entity Information
Jun. 06, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001865494
Document Type 8-K
Document Period End Date Jun. 06, 2024
Entity Registrant Name IO Biotech, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41008
Entity Tax Identification Number 87-0909276
Entity Address, Address Line One Ole Maaløes Vej 3
Entity Address, Postal Zip Code DK-2200
Entity Address, City or Town Copenhagen N
Entity Address, Country DK
City Area Code +45
Local Phone Number 7070 2980
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol IOBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos IO Biotech.
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos IO Biotech.